Follow-Up Pathways for Recurrent Fever: Evidence-Based Approaches for Clinical Practice

Abstract

Recurrent fever presents a diagnostic and management challenge across age groups, often signaling underlying systemic illness or specific syndromes. This review synthesizes recent evidence and clinical guidelines to establish structured follow-up pathways for recurrent fever, encompassing epidemiology, pathophysiology, risk stratification, diagnostic algorithms, therapeutic strategies, and emerging advances. The article aims to inform clinicians about practical, mechanism-based approaches to recurrent fever, integrating recent research and expert consensus to optimize patient outcomes.

Introduction

Recurrent fever is defined as three or more febrile episodes in a six-month period, separated by at least seven fever-free days. This phenomenon may reflect autoinflammatory syndromes, infectious etiologies, malignancies, or immune dysregulation. Accurate follow-up is essential for timely diagnosis and intervention, reducing morbidity and preventing complications. Despite advances in diagnostic technology, recurrent fever remains a source of significant clinical uncertainty, necessitating evidence-driven pathways for evaluation and management. Clinicians must balance a thorough search for underlying causes with the risk of overtreatment and unnecessary investigations, highlighting the need for clear, stepwise follow-up protocols.

Epidemiology / Disease Burden

The prevalence of recurrent fever varies by age and underlying etiology. In pediatric populations, periodic fever syndromes and recurrent infections are common, with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome accounting for a significant proportion of cases. In adults, recurrent fever is often associated with chronic infections, autoimmune diseases, and neoplastic processes. Epidemiological studies suggest that up to 10% of childhood fevers are recurrent, while in adults, recurrent fever accounts for approximately 1–2% of hospital admissions for febrile illness. The burden includes repeated healthcare visits, extensive diagnostic workups, and potential for delayed diagnosis of serious conditions, underscoring the importance of structured follow-up.

Pathophysiology

Recurrent fever arises from diverse mechanisms, including dysregulated innate immunity, persistent or relapsing infections, malignancy-related cytokine release, and genetic defects in inflammatory pathways. Autoinflammatory syndromes, such as familial Mediterranean fever and cryopyrin-associated periodic syndromes, are characterized by mutations affecting inflammasome function, leading to episodic cytokine surges. Chronic infections may involve incomplete pathogen clearance or immune evasion. Malignancies such as lymphoma can induce paraneoplastic fevers via proinflammatory cytokines. Understanding these mechanisms is critical to guiding targeted investigations and personalized follow-up strategies.

Risk Factors

Key risk factors for recurrent fever include genetic predisposition (notably in primary immunodeficiency or autoinflammatory syndromes), exposure to endemic pathogens, underlying chronic diseases, immunosuppression, and a history of malignancy. Pediatric patients with a family history of periodic fever syndromes, adults with autoimmune backgrounds, and individuals with occupational or travel exposure to infectious agents are at heightened risk. Early identification of risk factors facilitates stratification and tailored follow-up intensity.

Clinical Features

Clinical presentation varies by etiology. Autoinflammatory syndromes typically manifest with stereotyped episodes of fever, mucosal ulceration, pharyngitis, and lymphadenopathy. Infectious causes may present with localized symptoms during febrile episodes. Malignancies often feature constitutional symptoms such as weight loss, night sweats, or lymphadenopathy. A detailed history emphasizing fever pattern, associated symptoms, response to antipyretics, and intercurrent health is paramount. Physical examination should focus on lymphatic, musculoskeletal, and organomegaly findings, with attention to cutaneous or mucosal changes.

Diagnosis

Diagnostic evaluation of recurrent fever follows a tiered approach, integrating history, examination, and judicious use of laboratory and imaging modalities. Initial investigations include complete blood count, inflammatory markers (CRP, ESR), liver and renal function, and cultures as clinically indicated. Recurrent fever with systemic symptoms warrants expanded serology, autoantibody panels, and infectious disease screening. In children, monogenic periodic fever panels may be indicated. Imaging (ultrasound, CT, MRI) is reserved for cases with focal findings or systemic features suggestive of malignancy. Bone marrow biopsy or PET-CT may be required for persistent unexplained fever. Serial follow-up visits should reassess for evolving clinical features and revisit the differential diagnosis as new data emerge.

Treatment & Management

Management is etiology-specific. For autoinflammatory syndromes, colchicine, corticosteroids, and biologic agents targeting IL-1 or TNF-alpha pathways are mainstays. Infectious causes necessitate targeted antimicrobial therapy, while immune-deficient patients may require immunoglobulin replacement. Malignancy-associated fevers demand oncologic referral and disease-specific therapy. Supportive care, including antipyretics, hydration, and monitoring for complications, is universally applicable. Structured follow-up involves scheduled clinical assessments, monitoring for treatment response, and education for patients and families regarding symptom recognition and prompt reporting.

Recent Advances / Emerging Therapies

Recent advances include next-generation sequencing for rapid identification of monogenic periodic fever syndromes, as well as novel biologic agents such as IL-1 inhibitors (anakinra, canakinumab) and JAK inhibitors for refractory cases. Biomarker discovery (e.g., serum amyloid A, procalcitonin) is enhancing diagnostic discrimination between autoinflammatory, infectious, and neoplastic etiologies. Digital health solutions, including remote monitoring and telemedicine, are optimizing follow-up, permitting earlier intervention and improved longitudinal care.

Guideline Recommendations

Contemporary guidelines from the European League Against Rheumatism (EULAR), American College of Rheumatology (ACR), and Infectious Diseases Society of America (IDSA) advocate for algorithmic evaluation of recurrent fever, emphasizing early risk stratification, avoidance of diagnostic delay, and multidisciplinary collaboration. Regular reassessment and dynamic modification of the diagnostic and management plan are recommended, with specialist referral for complex or refractory cases. Patient and caregiver education forms a cornerstone of follow-up pathways.

Conclusion

Recurrent fever requires a systematic, evidence-based approach encompassing risk assessment, mechanism-informed diagnosis, and tailored management. Advances in genetic testing, biomarkers, and targeted therapies are reshaping follow-up strategies, enabling earlier diagnosis and improved outcomes. Adherence to guideline-directed pathways and multidisciplinary collaboration are essential for optimizing care in this challenging clinical scenario.